Oncology

  • 10 August 2020
    News

    BMS reports positive data of Opdivo plus Yervoy in MPM

    Bristol Myers Squibb (BMS) has reported positive data from the Phase III CheckMate -743 trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) in previously untreated, unresectable malignant pleural mesothelioma (MPM).

Close
Close
Close

Go Top